2:15 – 3:15 pm Saturday, October 30

Treating Smarter, Not Harder: Abandoning Intensification and Replacing with Immunotherapy for Patients with Down Syndrome and B-ALL (C234)

coglogoChildren with Down syndrome (DS) have a striking predisposition for developing acute leukemia, with a 40-fold increased risk of developing acute lymphoblastic leukemia (ALL) compared to non-DS patients (Wadhwa et al, 2017). Approximately 3% of children with ALL have DS, and these children have inferior outcomes and higher rates of treatment-related mortality (TRM) and are at greater risk of relapse (Buitenkamp et al., 2014).

Read more...

Pediatric Chemotherapy and Biotherapy Instructor Course (002)

The APHON Pediatric Chemotherapy and Biotherapy Instructor Course is designed for any nurse who has completed the provider course and meets the qualifications to be trained to teach the course. This course provides general instruction in adult education, guidance in the planning of lectures based on the APHON program content, and instruction in administering the provider exam. Upon successful completion, nurses return to their institutions as recognized APHON Pediatric Chemotherapy and Biotherapy Instructors who are able to provide ongoing instruction and education to other registered nurses.

Read more...
3:30 – 4:30 pm Thursday, October 28

Administration and Management of Anti-GD2 Immunotherapy for High Risk Neuroblastoma in the Outpatient Setting (200)

Neuroblastoma, the most common extracranial solid tumor in children, develops from neural crest cells that, typically, differentiate to form the sympathetic nervous system. Most neuroblastoma cases present as high-risk neuroblastoma, which has long been associated with high relapse rates and poor survival.

Read more...
Subscribe to this RSS feed